Tasrif Pharmaceutical is a biotech startup company founded in 2018. Tasrif Pharmaceutical’s focus is on aviral targeting of the poliovirus receptor (aka CD155). The poliovirus receptor (PVR) is overexpressed on numerous malignancies and PVR-TIGIT interaction has been identified as a novel checkpoint.
Tasrif Pharmaceutical’s lead molecule, TSRF 786C, is a hinge stabilized (S241P) IgG4 fully humanized monoclonal antibody against PVR. The USPTO has granted a patent for TSRF 786C and related antibodies and antibody fragments and their respective drug conjugates for the treatment of cancer.
TSRF 786C has been shown to block the PVR-TIGIT Checkpoint.
Tasrif Pharmaceutical is a preclinical stage company. No products are in clinical use and none of the products are FDA approved.
U87 MG tumor bearing mice bind the PREHUMANIZED Monoclonal Antibody AGAINST PVR in vivo. THERE is progressive accumulation of Antibody Conjugate IN the tumor in figure below .